Category - Markets

Cyclacel Pharmaceuticals

Brookline starts Cyclacel Pharma at buy; PT $22

Brookline Capital Markets initiated coverage of Cyclacel Pharmaceuticals (NASDAQ:CYCC) with a “buy” rating and $22 price target. The stock closed at $4.12 on May 18. Cyclacel is developing small molecule drugs targeting...

Onconova Logo

Maxim ups Onconova Therapeutics to buy; PT $1.25

Maxim Group upgraded Onconova Therapeutics (NASDAQ:ONTX) to “buy” from “hold” with a new price target of $1.25, citing a strengthened balance sheet, and a sufficient cash runway into the third quarter of 2021, well past...

Biocept Logo

Brookline starts Biocept at buy; PT $2.06

Brookline Capital Markets initiated coverage of Biocept (NASDAQ:BIOC) with a “buy” rating and price target of $2.06. The stock closed at 44 cents on May 13. Biocept is a molecular oncology diagnostics company that...

Artelo Biosciences Logo

Maxim cuts Artelo Biosciences to hold and removes PT

Maxim Group downgraded Artelo Biosciences (NASDAQ:ARTL) to “hold” from “ buy” without a price target, citing capital concerns. The stock closed at $1.22 on May 12, near the low end of its 52-week range of 61 cents to...

Genfit Logo

SVB Leerink slashes Genfit PT to $20 from $50

SVB Leerink slashed its price target for Genfit (NASDAQ:GNFT) to $20 from $50, but maintained its “outperform” rating, citing topline interim Phase 3 results that showed elafibranor failed to demonstrate a statistically...

Aimmune Therapeutics

HCW halves Aimmune Therapeutics PT to $15 from $30

H.C. Wainwright halved its price target for Aimmune Therapeutics (NASDAQ:AIMT) to $30 from $15, and reiterated its “neutral” rating, citing the pandemic’s impact on the launch of Palforzia, the first drug treatment of...

Endologix Logo

BTIG cuts Endologix to neutral; removes price target

BTIG downgraded Endologix (NASDAQ:ELGX) to “neutral” without a price target, citing “greater uncertainty” that the potential COVID-19 impact on revenue could put the company’s financial covenants in peril. The stock...


Analysts upgrade CymaBay Therapeutics and raise PTs

Analysts for Stifel, SVB Leerink and Roth Capital Partners upgraded CymaBay Therapeutics (NASDAQ:CBAY) and raised their price targets, citing a unanimous vote by an independent review that recommend further development...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.